Table 1.
Drugs approved by the US FDA with genetic indications.
| Drug | Indication | Gene(s) |
|---|---|---|
| Cetuximab | EGFR+/KRAS− metastatic colorectal cancer | EGFR and KRAS |
| Crizotinib | ALK+ non-small-cell lung cancer | ALK |
| Denileukin diftitox | CD25+ T-cell lymphoma (CD25 component of IL2-R) | IL2R |
| Everolimus | HER2-negative breast cancer | ERBB2 |
| Ivacaftor | Cystic fibrosis with G551D mutation in CFTR | CFTR |
| Lapatinib | HER2 positive (hormone receptor+) Metastatic breast cancer |
ERBB2 |
| Maraviroc | CCR5-tropic HIV infection | CCR5 |
| Panitumumab | Metastatic colorectal cancer KRAS negative |
KRAS |
| Pertuzumab | HER2+ metastatic breast cancer | ERBB2 |
| Trastuzumab | HER2+ overexpressing breast cancer | ERBB2 |
| Vemurafenib | Metastatic melanoma with BRAF V600E mutation | BRAF |